Cwm LLC Buys 10,560 Shares of Becton, Dickinson and Company $BDX

Cwm LLC grew its holdings in shares of Becton, Dickinson and Company (NYSE:BDX) by 87.7% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 22,596 shares of the medical instruments supplier’s stock after acquiring an additional 10,560 shares during the period. Cwm LLC’s holdings in Becton, Dickinson and Company were worth $3,892,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also recently modified their holdings of the business. Vanguard Group Inc. grew its position in shares of Becton, Dickinson and Company by 4.7% during the 1st quarter. Vanguard Group Inc. now owns 28,002,802 shares of the medical instruments supplier’s stock valued at $6,414,322,000 after acquiring an additional 1,259,750 shares during the period. T. Rowe Price Investment Management Inc. grew its position in shares of Becton, Dickinson and Company by 3.7% during the 1st quarter. T. Rowe Price Investment Management Inc. now owns 12,575,351 shares of the medical instruments supplier’s stock valued at $2,880,510,000 after acquiring an additional 448,644 shares during the period. Massachusetts Financial Services Co. MA grew its position in shares of Becton, Dickinson and Company by 10.8% during the 1st quarter. Massachusetts Financial Services Co. MA now owns 6,843,856 shares of the medical instruments supplier’s stock valued at $1,567,654,000 after acquiring an additional 667,957 shares during the period. JPMorgan Chase & Co. grew its position in shares of Becton, Dickinson and Company by 7.6% during the 1st quarter. JPMorgan Chase & Co. now owns 4,420,887 shares of the medical instruments supplier’s stock valued at $1,012,649,000 after acquiring an additional 312,124 shares during the period. Finally, Charles Schwab Investment Management Inc. grew its position in shares of Becton, Dickinson and Company by 1.2% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 3,091,149 shares of the medical instruments supplier’s stock valued at $707,872,000 after acquiring an additional 37,733 shares during the period. Institutional investors own 86.97% of the company’s stock.

Becton, Dickinson and Company Stock Down 0.9%

BDX opened at $185.08 on Friday. The firm has a 50-day simple moving average of $190.69 and a two-hundred day simple moving average of $185.17. Becton, Dickinson and Company has a 52 week low of $163.33 and a 52 week high of $251.99. The company has a market capitalization of $53.05 billion, a PE ratio of 33.29, a price-to-earnings-growth ratio of 1.46 and a beta of 0.25. The company has a quick ratio of 0.62, a current ratio of 1.10 and a debt-to-equity ratio of 0.69.

Becton, Dickinson and Company (NYSE:BDX) last released its quarterly earnings data on Thursday, April 14th. The medical instruments supplier reported $4.10 EPS for the quarter. Becton, Dickinson and Company had a net margin of 7.51% and a return on equity of 16.23%. The business had revenue of $5.32 billion during the quarter. Analysts forecast that Becton, Dickinson and Company will post 14.43 earnings per share for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, September 30th. Shareholders of record on Monday, September 8th were issued a dividend of $1.04 per share. This represents a $4.16 annualized dividend and a dividend yield of 2.2%. The ex-dividend date of this dividend was Monday, September 8th. Becton, Dickinson and Company’s dividend payout ratio is 74.82%.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on BDX. Morgan Stanley boosted their price objective on shares of Becton, Dickinson and Company from $196.00 to $197.00 and gave the company an “overweight” rating in a research report on Monday, August 11th. Wells Fargo & Company upped their target price on shares of Becton, Dickinson and Company from $172.00 to $184.00 and gave the stock an “equal weight” rating in a report on Friday, August 8th. Royal Bank Of Canada reaffirmed a “sector perform” rating and issued a $211.00 target price on shares of Becton, Dickinson and Company in a report on Thursday. Wall Street Zen raised shares of Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a report on Saturday, August 9th. Finally, Piper Sandler reaffirmed a “neutral” rating and issued a $200.00 target price (up previously from $185.00) on shares of Becton, Dickinson and Company in a report on Friday, August 8th. Three investment analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the stock. According to MarketBeat.com, Becton, Dickinson and Company has an average rating of “Hold” and a consensus target price of $205.40.

Insider Activity at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, Director Claire Fraser sold 917 shares of the stock in a transaction dated Wednesday, September 10th. The shares were sold at an average price of $187.50, for a total transaction of $171,937.50. Following the completion of the transaction, the director owned 22,226 shares of the company’s stock, valued at $4,167,375. This represents a 3.96% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Over the last ninety days, insiders have sold 1,838 shares of company stock worth $348,392. 0.36% of the stock is owned by corporate insiders.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.